A new generation of senolytic compounds is entering clinical trials. We review the most promising candidates, their mechanisms, and the regulatory pathway ahead for what may be the first genuinely disease-modifying longevity medicines.
A new generation of senolytic compounds is entering clinical trials. We review the most promising candidates, their mechanisms, and the regulatory pathway ahead for what may be the first genuinely disease-modifying longevity medicines.
What are senescent cells?
Cellular senescence is a state in which cells permanently cease dividing in response to damage or stress. While this mechanism originally evolved as a tumour-suppression tool, senescent cells that accumulate with age secrete a harmful cocktail of inflammatory signals known as the senescence-associated secretory phenotype (SASP). This chronic low-grade inflammation — sometimes called "inflammaging" — drives tissue dysfunction across virtually every organ system.
The accumulation of senescent cells has been causally linked to age-related conditions including osteoarthritis, atherosclerosis, type 2 diabetes, pulmonary fibrosis, neurodegeneration, and loss of physical function.
Senolytics: clearing the cellular debris of aging
Senolytics are compounds that selectively eliminate senescent cells. Unlike anti-inflammatory drugs that simply suppress SASP, senolytics remove the source of the problem. The concept was validated in landmark 2011 experiments by Baker et al., demonstrating that clearance of senescent cells in mice delayed the onset of multiple age-related pathologies and extended healthspan.
The leading senolytic candidates in 2026
Dasatinib + Quercetin (D+Q)
The most extensively studied senolytic combination. D+Q cleared senescent cells in early human trials with demonstrated improvements in physical function in patients with idiopathic pulmonary fibrosis. Multiple phase II trials are ongoing, including in Alzheimer's disease, diabetic kidney disease, and frailty.
Fisetin
A naturally occurring flavonoid found in strawberries, apples, and onions. Fisetin demonstrated potent senolytic activity in preclinical studies and is being evaluated in human trials for age-related physical decline and COVID-19 sequelae. Its natural origin and apparent safety profile make it an attractive candidate.
Navitoclax (ABT-263)
A BCL-2/BCL-XL inhibitor originally developed as an anti-cancer drug. Navitoclax demonstrates potent senolytic activity but carries risks of thrombocytopenia (platelet reduction) at doses effective for senolysis. Newer, more targeted derivatives aim to maintain senolytic efficacy with improved safety.
UBX0101 and UBX1325
Unity Biotechnology has developed MDM2 inhibitors targeting senescent cells in the eye (UBX1325, for diabetic macular oedema) and previously the joint (UBX0101). UBX1325 has shown promising phase II results in preserving vision in diabetic macular oedema patients.
"Senolytics represent the first genuine attempt to treat aging itself as a biological process amenable to pharmacological intervention — not just its downstream diseases." — Longevity World Group
Regulatory pathway and outlook
The FDA's designation of aging as a risk factor (rather than a disease) has historically complicated regulatory approval for longevity interventions. However, the FDA's TAME (Targeting Aging with Metformin) trial framework and growing recognition of geroscience are changing this landscape.
We expect the first senolytic compound to receive regulatory approval for a specific age-related indication — most likely pulmonary fibrosis or an ophthalmological condition — within the next three to five years. Approval in this context would establish an important precedent for subsequent applications.
What this means for clinical practice
For clinicians, the practical implications of effective senolytics are profound. Intermittent dosing regimens (rather than daily medication) may be effective, as senescent cells take months to re-accumulate after clearance. The goal is not indefinite drug dependency but periodic cellular "housekeeping" — a fundamentally new approach to preventive medicine.
